These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11786552)

  • 21. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
    Mosnier LO
    J Biol Chem; 2011 Jan; 286(1):502-10. PubMed ID: 21041299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
    Bajzar L
    Arterioscler Thromb Vasc Biol; 2000 Dec; 20(12):2511-8. PubMed ID: 11116046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage.
    Marx PF; Hackeng TM; Dawson PE; Griffin JH; Meijers JC; Bouma BN
    J Biol Chem; 2000 Apr; 275(17):12410-5. PubMed ID: 10777524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of protein C by the thrombin-thrombomodulin complex: cooperative roles of Arg-35 of thrombin and Arg-67 of protein C.
    Yang L; Manithody C; Rezaie AR
    Proc Natl Acad Sci U S A; 2006 Jan; 103(4):879-84. PubMed ID: 16418283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of thrombomodulin mutation causing defective thrombin binding with absence of protein C and TAFI activation.
    Okada M; Tominaga N; Honda G; Nishioka J; Akita N; Hayashi T; Suzuki K; Moriuchi H
    Blood Adv; 2020 Jun; 4(12):2631-2639. PubMed ID: 32556284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.
    Binette TM; Taylor FB; Peer G; Bajzar L
    Blood; 2007 Nov; 110(9):3168-75. PubMed ID: 17644733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.
    Incampo F; Carrieri C; Semeraro N; Colucci M
    Thromb Res; 2014 Nov; 134(5):1110-6. PubMed ID: 25193406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glu-192----Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin.
    Le Bonniec BF; Esmon CT
    Proc Natl Acad Sci U S A; 1991 Aug; 88(16):7371-5. PubMed ID: 1678522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.
    Ceresa E; Van de Borne K; Peeters M; Lijnen HR; Declerck PJ; Gils A
    J Biol Chem; 2006 Jun; 281(23):15878-83. PubMed ID: 16595693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex.
    Bajzar L; Morser J; Nesheim M
    J Biol Chem; 1996 Jul; 271(28):16603-8. PubMed ID: 8663147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of the endothelial protein C receptor on thrombin generation and clot lysis.
    Pepler L; Wu C; Dwivedi DJ; Wu C; Kim PY; Liaw PC
    Thromb Res; 2017 Apr; 152():30-37. PubMed ID: 28219843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombomodulin changes the molecular surface of interaction and the rate of complex formation between thrombin and protein C.
    Xu H; Bush LA; Pineda AO; Caccia S; Di Cera E
    J Biol Chem; 2005 Mar; 280(9):7956-61. PubMed ID: 15582990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis.
    Mishra N; Buelens K; Theyskens S; Compernolle G; Gils A; Declerck PJ
    J Thromb Haemost; 2012 Jun; 10(6):1091-9. PubMed ID: 22498006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase.
    Valnickova Z; Thøgersen IB; Potempa J; Enghild JJ
    J Biol Chem; 2007 Feb; 282(5):3066-76. PubMed ID: 17138567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation.
    Mosnier LO; Elisen MG; Bouma BN; Meijers JC
    Thromb Haemost; 2001 Oct; 86(4):1057-64. PubMed ID: 11686324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI)--a comparative study assessing the biological equivalence of rat, murine and human TAFI.
    Hillmayer K; Macovei A; Pauwels D; Compernolle G; Declerck PJ; Gils A
    J Thromb Haemost; 2006 Nov; 4(11):2470-7. PubMed ID: 17002650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcium-dependent activation of protein C by thrombin/thrombomudulin: role of negatively charged amino acids within the activation peptide of protein C.
    Friedrich U; Pötzsch B; Preissner KT; Müller-Berghaus G; Ehrlich H
    Thromb Haemost; 1994 Oct; 72(4):567-72. PubMed ID: 7878634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of TAFI function through different pathways--implications for the development of TAFI inhibitors.
    Gils A; Ceresa E; Macovei AM; Marx PF; Peeters M; Compernolle G; Declerck PJ
    J Thromb Haemost; 2005 Dec; 3(12):2745-53. PubMed ID: 16359512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction.
    Toh CH
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S69-71. PubMed ID: 14567541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor.
    Marx PF; Havik SR; Bouma BN; Meijers JC
    J Thromb Haemost; 2005 Jun; 3(6):1293-300. PubMed ID: 15946220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.